Related Experiment Video
Updated: Feb 20, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Celastrol downregulates E2F1 to induce growth inhibitory effects in hepatocellular carcinoma HepG2 cells
Liang Ma1, Lei Peng1, Sheng Fang1
1Department of Chemical Biology and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Anhui University of Technology, Ma'anshan, Anhui 243002, P.R. China.
Abstract:
Celastrol, a natural compound extracted from Tripterygium wilfordii, is known to exhibit potential anticancer activities in various types of tumor cells. E2F1 is reported to be overexpressed in several types of human tumors and its inactivation may be a valuable novel potential therapeutic strategy for cancer treatment. However, the molecular mechanism underlying the pro-apoptotic effects of celastrol on hepatocellular carcinoma (HCC) cells remains unclear, and E2F1-targeted compounds have been rarely identified. In the present study, we demonstrated that celastrol inhibited the proliferation of human HCC cells and triggered apoptosis of HepG2 cells in a caspase-dependent manner. E2F1 was potently downregulated by celastrol in a dose- and time-dependent manner at both the mRNA and protein levels. Moreover, siRNA-mediated E2F1 silencing enhanced celastrol-induced apoptosis and inhibition of proliferation. Our data imply that downregulation of E2F1 may be a key factor in the celastrol-mediated inhibitory effects in HepG2 cells, and celastrol can serve as a leading compound for the development of compounds designed to inactivate E2F1 for HCC therapy.
Insights
Celastrol, a natural compound, inhibits hepatocellular carcinoma (HCC) cell growth by downregulating E2F1. This suggests celastrol as a potential therapeutic leading compound for HCC treatment targeting E2F1.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Celastrol from Tripterygium wilfordii shows anticancer potential.
- E2F1 overexpression is common in human tumors, making it a therapeutic target.
- The mechanism of celastrol's apoptosis-inducing effects in hepatocellular carcinoma (HCC) and E2F1 targeting are not fully understood.
Purpose of the Study:
- To investigate the molecular mechanism of celastrol's pro-apoptotic effects on HCC cells.
- To determine if celastrol affects E2F1 expression in HCC.
- To evaluate celastrol as a potential therapeutic agent for HCC targeting E2F1.
Main Methods:
- Human HCC cells (HepG2) were treated with celastrol.
- Cell proliferation and apoptosis were assessed.
- E2F1 expression was analyzed at mRNA and protein levels.
- Small interfering RNA (siRNA) was used to silence E2F1.
Main Results:
- Celastrol inhibited HCC cell proliferation and induced apoptosis in a caspase-dependent manner.
- Celastrol dose- and time-dependently downregulated E2F1 mRNA and protein levels.
- E2F1 silencing amplified celastrol-induced apoptosis and proliferation inhibition.
Conclusions:
- Celastrol's inhibitory effects on HepG2 cells are linked to E2F1 downregulation.
- Celastrol shows promise as a lead compound for developing E2F1-inactivating drugs for HCC therapy.
More Related Videos
08:50In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
10:36Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
Published on: March 17, 2016
Related Concept Videos
Mitogens and the Cell Cycle
Cell Specific Gene Expression
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...